Facebook
Twitter
Telegram
Report an ErrorVascular Biogenics Ltd. Balance Sheet 2011-2024 | VBLT
Annual Balance Sheet Vascular Biogenics Ltd.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-19.6 M | -10.7 M | -6.5 M | -28.6 M | -6.69 M | -11.6 M | -7.09 M | -36.8 M | 28.7 M | -1.22 M | - | ||
Long Term Debt |
263 K | - | 1.82 M | - | 2.17 M | 449 K | - | - | - | - | 31 M | - | - |
Long Term Debt Current |
445 K | 361 K | 529 K | 393 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 2.56 M | 3.33 M | 4.05 M | 2.81 M | 2.22 M | 86 K | 70 K | 110 K | 31.2 M | 130 K | - |
Total Current Liabilities |
2.74 M | 2.01 M | 9.93 M | 7.46 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.43 M | 7.13 M | 12.5 M | 10.8 M | 12.8 M | 7.58 M | 9.79 M | 4.87 M | 4.23 M | 3.04 M | 35.4 M | 2.55 M | - |
Deferred Revenue |
- | - | 658 K | 725 K | 386 K | 290 K | 1.05 M | - | - | - | - | - | - |
Retained Earnings |
-82.3 M | -71 M | -262 M | -232 M | -200 M | -181 M | -165 M | -155 M | -139 M | -127 M | -110 M | -92.4 M | - |
Total Assets |
19.5 M | 5.51 M | 64.7 M | 41.7 M | 48.6 M | 60.7 M | 65.7 M | 47.3 M | 39.2 M | 38.1 M | 11.8 M | 15.2 M | - |
Cash and Cash Equivalents |
11.8 M | 1.58 M | 22 M | 13.2 M | 9.44 M | - | - | - | - | - | - | - | - |
Book Value |
15.1 M | -1.62 M | 52.2 M | 30.9 M | 35.8 M | 53.1 M | 55.9 M | 42.4 M | 35 M | 35.1 M | -23.6 M | 12.7 M | - |
Total Shareholders Equity |
15.1 M | -37 M | 50.6 M | 30.9 M | 36 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Vascular Biogenics Ltd.
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | 1.66 M | 1.82 M | 1.88 M | 1.95 M | 1.97 M | 2.03 M | - | - | - | 99 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 108 K | 459 K | 477 K | - | - | 2.44 M | 2.56 M | 2.69 M | 2.9 M | 3.09 M | 3.33 M | - | - | - | 4.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.6 M | 5.41 M | 8.21 M | 7.21 M | - | - | 13.5 M | 12.5 M | 10.3 M | 11.5 M | 9.82 M | 10.8 M | - | - | - | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 546 K | 658 K | 679 K | 752 K | 713 K | 725 K | - | - | - | 386 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-299 M | -298 M | -297 M | -294 M | - | - | -273 M | -262 M | -253 M | -246 M | -238 M | -232 M | - | - | - | -208 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
20.9 M | 24.6 M | 28.1 M | 29.7 M | - | - | 56.3 M | 64.7 M | 61.1 M | 67.3 M | 47.1 M | 41.7 M | - | - | - | 49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.8 M | 24.3 M | 26.1 M | 17.7 M | 18.3 M | 15.1 M | 13.3 M | 22 M | 25.3 M | 31.7 M | 24.2 M | 13.2 M | 11.6 M | 16.7 M | 12.9 M | 9.44 M | - | - | - | 29.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
18.3 M | 19.2 M | 19.9 M | 22.5 M | - | - | 42.8 M | 52.2 M | 50.8 M | 55.9 M | 37.3 M | 30.9 M | - | - | - | 36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
18.3 M | 19.2 M | 19.9 M | 22.5 M | 25.3 M | 34.4 M | 42.8 M | 50.6 M | 49.2 M | 54.3 M | 35.7 M | 30.9 M | 37.4 M | 42.7 M | 31.6 M | 36 M | - | - | - | 53.2 M | - | - | - | 56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency